A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
for Extensive-Stage Small Cell Lung Cancer
Drug: Atezolizumab
20 locations incl. Daphne
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT06646276·Phase 3·Recruiting